Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis
Hepatology International, 06/06/2012
Witjes CDM et al. – GP73 is a valuable serum marker that seems to be superior to alpha–fetoprotein (AFP) and can be useful in the diagnosis and screening of hepatocellular carcinoma (HCC). Although GP73 may improve the detection and treatment of one of the most common malignancies worldwide, additional research is required.Methods
- A systematic search of PubMed, Embase, and Web of Science was performed for articles published between January 2005 and October 2010, and focusing on biomarkers for HCC in urine, serum, or saliva.
- Data on sensitivity and specificity of tests were extracted from each included article and displayed with a summary ROC.
- A meta-analysis was carried out in which the area under the curve for each biomarker was used to compare the accuracy of different tests.
- In seven well-defined studies, three biomarkers were identified for potential use, namely, Golgi protein 73 (GP73), interleukin-6 (IL-6), and squamous cell carcinoma antigen (SCCA).
- Comparison with AFP showed that GP73 was superior (p=0.006; 95 % CL -0.23, -0.12), IL-6 was similar (p=0.66; 95 % CL -0.31, 0.25), and SCCA was inferior to AFP (p=0.001; 95 % CL 0.12, 0.23).